Hahn Mark W's Form 4 filing
Verona Pharma plc (VRNA) · filed Nov 26, 2024
- Accession no.
- 0001104659-24-123211
- Filed
- Nov 26, 2024
- Trade date
- Nov 25-26, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $12.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hahn Mark WCIK 0001408502 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2024 | Ordinary Shares | SSaleDisposed | −1,600 | $5.00 | −$8,000 | 14,289,736 | Direct | |
| Nov 26, 2024 | Ordinary Shares | SSaleDisposed | −800 | $5.00 | −$4,000 | 14,288,936 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.